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An increasing interest in novel foods,
including those developed from genetically
modiﬁed (GM) crops, has resulted in debate
about the likelihood and source of potential
adverse health effects and how the safety of
new foods can best be assured (FAO/WHO
2000; Flamm 2001; Goldman 2000;
Hodgson 2001; Kuiper et al. 1999, 2001;
Lachmann 1999). In this context, a major
focus has been on allergenicity and consider-
ation of whether the product of a novel gene
introduced into a crop plant will display the
ability to induce or elicit allergic sensitiza-
tion among consumers, or whether transfor-
mation will in some other way influence
allergenic potential. The requirements for
evaluation of the potential allergenic activity
of novel foods have been reviewed in some
detail (FAO/WHO 2001; Kimber et al.
1997, 1999; Kimber and Dearman 2001a;
Metcalfe et al. 1996; Taylor 1997; Taylor
and Heﬂe 2001). The concern is legitimate,
and there is clearly a need to develop meth-
ods and strategies that will allow the accu-
rate identiﬁcation of sensitizing hazard.
The ﬁrst attempt to address this issue in
a systematic way was undertaken by the
International Life Sciences Institute (ILSI)
Allergy and Immunology Institute in collab-
oration with the International Food
Biotechnology Council (IFBC). This initia-
tive resulted in a report that recommended a
hierarchical approach to safety assessment
(Metcalfe et al. 1996). The proposal was
that the route taken in assessing safety
depends on whether the gene product of
interest derived from a source known to be
associated with allergic disease in humans.
Included in the testing strategies were the
following components: consideration of the
serologic identity of a novel protein with
proteins implicated as human allergens;
assessment of the structural similarity to, or
amino acid sequence homology with, aller-
genic proteins; and measurement of the
resistance of the novel protein to proteolytic
digestion in a simulated gastric fluid
(Metcalfe et al. 1996). These recommenda-
tions provided for the ﬁrst time a conceptual
and practical framework for safety evalua-
tions. However, it must be acknowledged
that, although collectively the methods listed
above are a source of valuable information
about the properties of novel proteins and
allow identification of proteins that are
likely to cause sensitization on the basis of
their structural similarity to known aller-
gens, they do not provide a deﬁnitive assess-
ment of inherent sensitizing potential.
Consequently, there has been considerable
interest in the possibility of developing
appropriate animal models.
The report of the ILSI/IFBC deliberations
was guarded about the possible application of
animal models and considered then that no
suitable methods were available. In the inter-
vening period, however, progress has been
made. In 2001 a special consultation panel
was convened by the Food and Agriculture
Organization and the World Health Organi-
zation to review and, if necessary, revise the
recommendations made previously by
ILSI/IFBC (FAO/WHO 2001). One of the
conclusions reached by that consultation was
that animal models might contribute valuable
information regarding the likely allergenicity
of foods derived from GM crops. This view
has provided further impetus to the develop-
ment and application of animal models,
specifically those based on studies in mice,
rats, and other species. In this article, we dis-
cuss progress in the evaluation of a method
using BALB/c mice. However, before review-
ing the details of this approach, it is necessary
to consider brieﬂy the scientiﬁc background to
allergenicity assessment.
Scientiﬁc Context
allergy is an important health issue; the preva-
America is 1–2%, with a prevalence among
infants of approximately 5% (Helm and
Burks 2000). In these regions, more than
80% of food allergies are thought to be asso-
ciated with a limited range of produce: specif-
ically peanuts, tree nuts, eggs, cows’ milk,
wheat, soybeans, ﬁsh, and shellﬁsh (Bush and
Hefle 1996; Hefle et al. 1996; Sampson
1988; Young et al. 1994). It is apparent,
however, that significant geographic differ-
ences exist regarding the frequency with
which certain foods are implicated as the
cause of food allergy, and these differences
derive primarily from variations in dietary
preferences (Hourihane 1998).
Predisposition and exposure. Several
factors determine interindividual differences
in susceptibility to food allergy and whether
or not sensitization will be acquired
(Figure 1). Probably chief among these is
genetic predisposition and inheritance of an
atopic phenotype (Rowntree et al. 1985;
Ruiz et al. 1992). It is clear also that expo-
sure plays a pivotal role in the pathogenesis
of food allergy. One reflection of this is the
fact that although a predisposition to mount
Address correspondence to I. Kimber, Syngenta
Central Toxicology Laboratory, Alderley Park,
Macclesfield, Cheshire SK10 4TJ UK. Telephone:
44-1625-515408 Fax: 44-1625-590996. E-mail:
ian.kimber@syngenta.com
This article is part of the mini-monograph
“Animal Models to Detect Allergenicity to Foods
and Genetically Modiﬁed Products.”
Received 9 April 2002; accepted 10 September 2002.
There is considerable interest in the design of approaches that will permit the accurate identiﬁcation
and characterization of proteins that have the inherent potential to induce sensitization and cause
food allergy. Among the methods used currently as part of such assessments are consideration of
structural similarity to, or amino acid sequence homology with, known human allergens; whether
there exists immunologic cross-reactivity with known allergens; and measurement of resistance to
proteolytic digestion in a simulated gastric ﬂuid. Although such approaches provide information that
will contribute to a safety assessment, they do not—either individually or collectively—provide a
direct evaluation of the ability of a novel protein to cause allergic sensitization. For this reason, work
is in progress to design and evaluate suitable animal models that will provide a more holistic assess-
ment of allergenic potential. In this laboratory, the approach we have taken has been to examine the
characteristics of immune responses induced in mice following parenteral (intraperitoneal) exposure
to test proteins. The basis of this method is to determine simultaneously the overall immunogenic
compare this with their ability to provoke IgE antibody production, IgE being the antibody that
effects allergic sensitization. Although this approach has not yet been evaluated fully, the results
available to date suggest that it will be possible to distinguish proteins that have the inherent poten-
tial to induce allergic sensitization from those that do not. In this article we summarize progress to
date in the context of the scientiﬁc background against which such methods are being developed.
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potential of proteins [measured as a function of immunoglobulin (Ig) G antibody responses] and to
protein allergy, T lymphocytes. Environ Health Perspect 111:227–231 (2003). [Online 21 January 2003]     Natural history of food allergy. True food
lence among adults in Europe and Northand sustain immunoglobulin (Ig) E antibody
responses (atopy) is heritable, the particular
proteins and foods against which allergic
responses will be directed appears not to be
genetically programmed. The assumption is
that, against a background of increased
generic susceptibility, it is the nature, route,
extent, and duration of exposure and the
time at which such exposure occurs that will
determine the foods to which a subject may
acquire sensitization.
The influence of exposure parameters is
currently of considerable interest, in particular,
the possible importance of exposure in utero
and via breast-feeding. There is interest also in
the extent to which sensitization to food pro-
teins can be induced by topical or inhalation
exposure to the causative allergen or to an
immunologically cross-reactive protein.
Immune and allergic responses. Not-
withstanding considerations of individual
predisposition and the nature of exposure, the
critical event in the development of sensitiza-
tion is the elicitation of an immune response.
By deﬁnition, “allergy” describes the adverse
health effects that may result from the induc-
tion of a speciﬁc immune response. Although
other (cell-mediated) immune reactions may
be critical in some circumstances (e.g., celiac
disease associated with gluten sensitivity), it is
IgE antibody-dependent mechanisms that are
most commonly implicated in food allergy.
The acquisition of sensitization depends
therefore on the initiation of an immune
response of sufﬁcient vigor and of the quality
required to sustain IgE antibody production.
Such IgE antibody will distribute systemically
and associate with speciﬁc receptors expressed
by mast cells and basophils. If the now-sensi-
tized individual is exposed subsequently to
the same allergen or to an immunologically
cross-reactive allergen, then an allergic reac-
tion will be provoked. Antigen will bind to,
and cross-link, mast cell–associated speciﬁc IgE
antibody, and this in turn will precipitate cel-
lular activation and degranulation, resulting in
the release of an array of inﬂammatory media-
tors (e.g., histamine, serotonin, leukotrienes,
and prostaglandin). These mediators will act in
concert to initiate inﬂammation and the symp-
toms of an allergic reaction. These symptoms
commonly include nausea and vomiting,
abdominal pain, flatulence, and diarrhea.
However, other organ systems may also be
involved, speciﬁcally, the skin (acute urticaria
and angioedema, and atopic dermatitis) and
the respiratory tract (allergic rhinitis and
asthma). Occasionally, severe systemic (ana-
phylactic) reactions are induced (Sampson
1999).
The initiation and maintenance of
IgE antibody production depend on the
development of a selective type 2 immune
response. It has been recognized for some
time that the quality of adaptive immune
responses reﬂects in large part functional het-
erogeneity among T lymphocytes. Such
functional diversity was ﬁrst characterized in
CD4+ T helper (Th) cell populations.
Although the situation is complex, two main
populations of Th lymphocytes have been
identified (designated Th1 and Th2 cells)
that develop from common precursors dur-
ing the evolution of an immune response.
These subsets differ primarily in their
cytokine secretion patterns. The relevance of
this for the pathogenesis of food allergy and
other forms of atopic disease is that IgE anti-
body production depends on the availability
of interleukin (IL) 4, a product of Th2 cells
but not of Th1 cells. Moreover, IL-4 and
other cytokine products of Th2 cells
(notably, IL-10 and IL-13) favor the expres-
sion of immediate-type allergic reactions.
Conversely, Th1 cells antagonize acute aller-
gic reactions, and interferon γ, a cytokine
secreted by Th1 cells, inhibits IgE antibody
production. More recently, it has become
apparent that there also exists heterogeneity
among CD8+ T cytotoxic (Tc) lymphocytes,
with Tc1 and Tc2 subsets displaying
cytokine expression proﬁles comparable with
their Th1 and Th2 counterparts, respectively
(Corry and Kheradmand 1999; Kimber and
Dearman 1997; Mosmann et al. 1986;
Mosmann and Coffman 1989; Mosmann
and Sad 1996; Stevens et al. 1988).
On this basis, therefore, it is clear that the
effective development of allergic sensitization
to food proteins will require the stimulation
of a preferential type 2 immune response and
the elaboration of speciﬁc IgE antibody. The
corollary is that not all immune responses will
result in allergic sensitization and adverse
health effects.
Oral tolerance. It is not uncommon for
immune responses to dietary proteins to be
viewed as having two possible outcomes:
priming for allergic sensitization, or the
development of tolerance resulting in
immunologic unresponsiveness. On this
basis, food allergy has been characterized as
reflecting a breakdown in tolerance (Strobel
1997). Although this is an attractively sim-
ple paradigm, the reality is rather more com-
plex.
Conceptually, the phenomenon of oral
tolerance is well established experimentally,
and at least some of the important immuno-
logic mechanisms have been described
(Brandtzaeg 1996; Mowat 1987; Strobel
1997; Strobel and Mowat 1998). There is
even some rather limited, and mostly circum-
stantial, evidence that in humans oral expo-
sure to antigens may down-regulate specific
immune responses (Husby et al. 1994;
Lowney 1973; Van Hoogstraten et al. 1991).
However, oral tolerance is not an absolute
phenomenon and most commonly manifests
as a down-regulation in some but not all
aspects of immune responsiveness. In general
terms, T-lymphocyte responses and IgE anti-
body production are more readily down-regu-
lated (and with lower doses of antigen) than
is IgG production (Strobel 1997). It is there-
fore inappropriate to regard oral tolerance as
immunologic unresponsiveness; the more
accurate descriptors would be hyporespon-
siveness, or possibly partial responsiveness.
Because immunologic tolerance is incom-
plete, it is not unexpected that IgG antibodies
speciﬁc for food proteins are found in normal
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Figure 1. A diagrammatic summary of the major factors affecting susceptibility to the acquisition of food
allergy.
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Sensitizationsubjects with no signs or symptoms of food
allergy (Barnes 1995; Barnes et al. 1983,
1988; Johansson et al. 1984). The important
point is that dietary proteins can elicit IgG
responses that are apparently without ill
effect, or IgE responses that (if of sufficient
vigor) will induce sensitization. Indeed, one
may speculate that the normal situation is for
the elicitation of IgG antibody responses to
dietary proteins, which will of course in
almost all instances be potentially immuno-
genic and will be recognized as foreign by the
host immune system. Indeed, IgG responses
to food proteins may provide a beneficial
mechanism for clearing proteins or peptides
that have been absorbed inadvertently from
the gastrointestinal tract.
Role of antigen. It will be apparent from
the considerations summarized above that the
successful acquisition of sensitization will be
determined by the congenital or acquired sus-
ceptibility of the subject, the conditions and
timing of exposure, and the characteristics of
induced immune responses. The other key
element is the nature of the food proteins
themselves. An argument could be made that
given appropriate levels of exposure, it might
be possible to induce allergic responses to any
protein, particularly if a suitable adjuvant were
used. In practice, however, this is not the case,
and only a minority of food proteins has been
implicated as causes of food allergy. Given
that such differences exist, the important
question is what factors distinguish protein
allergens from other proteins that, despite
being inherently immunogenic, fail to cause
allergic sensitization. The question is probably
best posed as follows: What characteristics
confer on proteins the ability to induce aller-
gic sensitization? In fact, there is no clear
answer to this question, although it would
appear that among the important variables are
the size of the protein, glycosylation status,
biologic function (e.g., enzymatic activity),
resistance to proteolytic digestion, overall
immunogenicity and the way in which the
protein is recognized, internalized, and
processed by antigen-presenting cells, and the
manner in which peptides are presented to
responsive T lymphocytes (Aalberse 2000;
Astwood et al. 1996; Bredehorst and David
2001; Bufe 1998; Huby et al. 2000).
Regardless of a detailed understanding of
the biologic and/or structural properties of
proteins that govern their differential sensitiz-
ing activity, attempts to identify inherent
allergenic hazard in the context of a safety
assessment are predicated on the basis of
being able to model such differences experi-
mentally. Thus, animal methods proposed for
characterization of the sensitizing potential of
proteins have focused on measurement of
induced IgE antibody responses and/or the
elicitation of IgE antibody-dependent allergic
reactions. The approach we have taken using
BALB/c mice is summarized below.
Allergy Assessment Method
using BALB/c Strain Mice
General considerations. Although mouse
models of food allergy and food anaphylaxis
are available, for example those described by
Li and colleagues (Li et al. 1999, 2000, 2001),
they are not necessarily suitable for the pur-
poses of hazard identiﬁcation in the context of
a safety assessment. In attempting to develop
an approach that will be appropriate for haz-
ard characterization, a number of general
issues should be addressed.
The ﬁrst of these is the species and strain
of choice. We have elected to focus on the use
of mice largely because for this species there is
a sophisticated appreciation of the immune
response, coupled with the availability of a
range of reagents. The selection of BALB/c
strain mice was based on an understanding
that such mice are high IgE responders,
which in this context may be regarded as
equivalent to an atopic phenotype.
Perhaps the most contentious issue is that
of the preferred route of exposure. Although it
might appear initially that oral administration
represents the most appropriate route of expo-
sure for a method designed to identify poten-
tial food allergens, this is not necessarily the
case. For instance, there is reason to believe
that exposure via the diet or in drinking water
is more likely in rodents to cause immuno-
logic hyporesponsiveness than sensitization.
Thus, experience in rats has shown that
ad libitum exposure to ovalbumin (OVA; a
known human allergen) failed to induce IgE
antibody responses in Brown Norway rats
(Knippels et al. 1998b). Moreover, in our
hands, at least, even gavage exposure appears
to be considerably less sensitive than par-
enteral administration with respect to eliciting
IgE antibody responses in BALB/c mice
(Dearman et al. 2001). For these reasons, we
have chosen to focus primarily, but not exclu-
sively, on assessment of immune responses
induced in mice after intraperitoneal adminis-
tration of protein. Of course, this approach
will not necessarily reflect what will happen
regarding the induction of mucosal immune
responses after normal dietary encounter with
a food protein allergen. However, in the con-
text of providing a method of the sensitivity
required for hazard identiﬁcation and charac-
terization and for evaluating the inherent
potential of a protein to induce the quantity
and quality of an immune response required
for the elicitation of an IgE response, this is
the most appropriate approach.
A final generic issue that is worth
addressing is the option for the use of adju-
vant. There is no doubt that combining
exposure to antigen with adjuvant adminis-
tration will augment induced immune
responses, and that some adjuvants (e.g.,
cholera toxin) are used to potentiate IgE
antibody responses (Li et al. 1999, 2000,
2001). However, the danger of employing
such a strategy is that increased sensitivity
will be gained at the cost of a loss of selectiv-
ity. That is, some adjuvants may have the
ability to confer on inherently nonallergenic
proteins the potential to provoke IgE anti-
body production, thereby generating what
are in effect false-positive responses.
Of course, other variables are worthy of
consideration and may or may not affect the
sensitivity, selectivity, and overall accuracy of
an approach such as this. Among such con-
siderations are the dosing regimen and the
age and sex of the animals. We are currently
exploring the potential impact of some of
these variables.
Current approach. Against this back-
ground, our approach currently is to use young
adult (8–12 week) female BALB/c mice. The
basic strategy is to examine the characteristics of
immune responses provoked in these animals at
various periods after intraperitoneal exposure
(two injections, 7 days apart) to the test pro-
tein. To this end, IgG antibody responses are
measured using enzyme-linked immunosorbent
assays (ELISAs), and IgE antibody responses
are measured using homologous passive cuta-
neous anaphylaxis (PCA) assays (Figure 2).
Experiences with this and similar protocols
have been described and reviewed comprehen-
sively elsewhere (Dearman et al. 2000, 2001;
Dearman and Kimber 2001; Hilton et al.
1994, 1997; Kimber and Dearman 2001b), so
a detailed consideration is unnecessary here.
Mini-Monograph | Protein allergy assessment in mice
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Figure 2. A schematic summary of the current
approach for assessment of the inherent allergenic
potential of proteins using BALB/c mice. Immuno-
genicity (IgG antibody production) is measured
using ELISAs, and allergenicity (IgE antibody pro-
duction) is measured using homologous PCA
assays.
Bleed
IgG
ELISA
Primary exposure
Secondary exposure
IgE
PCA
7 days
7–21 daysCollectively, we have been able to demon-
strate that this approach can discriminate
among proteins on the basis of their relative
ability to provoke IgE antibody responses.
Thus, under conditions of exposure where
proteins were found to elicit IgG responses of
comparable vigor, substantial differences were
observed with respect to IgE antibody produc-
tion. Such differences are even more marked
when viewed in the context of the differential
doses required to elaborate antibody responses.
Consideration of a representative experiment
serves to illustrate the point.
Groups of mice (n = 5) were exposed by
intraperitoneal injection to 0.25 mL of phos-
phate-buffered saline containing 0.1% peanut
lectin [a minor peanut allergen (Burks et al.
1994)], 2% OVA, or 10% potato protein
extract [PPE; containing proteins that are
considered not to possess signiﬁcant sensitiz-
ing potential (Dearman et al. 2001)]. This
treatment was repeated 7 days later, and in
this experiment all mice were exsanguinated 2
weeks after the initiation of exposure. Serum
was prepared and IgG and IgE antibody levels
measured. The results of this experiment are
illustrated in Figure 3. The data reveal that
each of the proteins was able to induce in
mice a vigorous IgG antibody response. In
contrast, however, there were signiﬁcant dif-
ferences in IgE antibody responses. Although
both peanut lectin and OVA provoked high-
titer IgE antibody production, only a very
low-grade response was seen with PPE.
From these and similar investigations, our
view currently is that this approach allows
discrimination among proteins in terms of
their ability to provoke IgE responses and
that, on this basis, it is possible to identify
those proteins that have an inherent potential
to cause allergic sensitization.
Finally, it must be emphasized that hazard
identiﬁcation represents only the ﬁrst step in
any safety evaluation or risk assessment
process. It is our view that the results of exper-
iments in which inherent sensitizing potential
is measured must be incorporated into an
holistic safety assessment that also includes
consideration of the sites and levels of expres-
sion of the protein of interest in modified
crops plants and the likely exposure of con-
sumers to foods or food products derived
from such crops. Clearly, it is important also
to consider data from animal models in paral-
lel with information relating to the structural
similarity to, or sequence homology with,
known allergens; resistance to digestion by
simulated gastric ﬂuid or pepsin; and the pres-
ence or absence of serologic identity with
known protein allergens. A holistic approach
such as this will provide a rational basis for
future safety assessments. In the meantime,
there is a pressing need to evaluate more
extensively the sensitivity, selectivity, and
overall reliability of this and other proposed
animal models.
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Figure 3. Groups of BALB/c mice (n = 5) received 0.25 mL of 0.1% peanut lectin, 2% OVA, or 10% PPE in
phosphate-buffered saline by intraperitoneal injection on days 0 and 7. Fourteen days after the initiation of
exposure, animals were exsanguinated and serum samples prepared. (A) Individual serum samples were
tested for the presence of IgG antibody by ELISA. IgG titer is recorded as the highest dilution at which sub-
strate conversion [optical density at 450 nm (OD450 reading)] was ≥ 0.5. For control sera derived from naive
(untreated) mice, OD450 readings never exceeded this value, even at the maximum concentration tested
(1 in 25) in all ELISAs. Data are expressed as mean and SE of IgG reciprocal titer (log2) for each treatment
group. Serum samples were pooled on an experimental group basis; serial doubling dilutions were pre-
pared and used to derive IgE antibody titers by homologous PCA assay, using four naive recipient mice per
sample. (B) In every analysis, pooled serum samples from naive (untreated) animals were tested concur-
rently and were uniformly negative at the maximum concentration used (data not shown). IgE antibody titer
is recorded as the highest dilution of serum resulting in a positive PCA reaction in most recipient animals.
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